Form 4: Intellia CEO Sells Shares for Tax Obligations

Intellia Therapeutics CEO John M. Leonard sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations related to RSU vesting.

Summary

• John M. Leonard, President and CEO of Intellia Therapeutics, Inc. (NTLA), reported a transaction on January 5, 2026.
• He disposed of 34,146 shares of Intellia Therapeutics Common Stock at a price of $9.21 per share.
• This transaction was a mandatory "sell-to-cover" to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2026.
• The sale was not a volitional trade by Mr. Leonard.
• Following the transaction, Mr. Leonard directly beneficially owns 1,013,339 shares and indirectly owns 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a mandatory 'sell-to-cover' for tax purposes upon RSU vesting, which is a routine event and does not reflect a volitional investment decision by the insider, thus indicating a neutral sentiment.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction for tax purposes and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact, as the transaction is a non-volitional sale for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

The reported transaction is a mandatory 'sell-to-cover' to satisfy tax obligations upon RSU vesting, not a volitional sale based on investment sentiment. Therefore, it does not provide a basis for changing an investment recommendation.

Keywords

Intellia Therapeutics, NTLA, Form 4, insider transaction, stock sale, CEO, RSU, tax withholding, John M. Leonard